Our pipeline

We have an exciting and balanced pipeline underpinned by great science.

Home / Our therapy areas / Our pipeline

Latest quarterly updates

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.


178

projects in our pipeline

17

new molecular entities in our late-stage pipeline

3

new molecular entities under review

Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).


Oncology (as of 8 February 2024)

Phase I

Phase I

Phase II

Phase II

Phase III

Phase III

LCM Projects

LCM Projects

Cardiovascular, Renal and Metabolism (as of 8 February 2024)

Phase I

Phase I

Phase II

Phase II

Phase III

Phase III

LCM Projects

LCM Projects

Respiratory & Immunology (as of 8 February 2024)

Phase I

Phase I

Phase II

Phase II

Phase III

Phase III

LCM Projects

LCM Projects

Rare Disease (as of 8 February 2024)

Phase I

Phase I

Phase II

Phase II

Phase III

Phase III

LCM Projects

LCM Projects

Vaccine & Immune therapies (as of 8 February 2024)

Phase I

Phase I

Phase II

Phase II

Phase III

Phase III

LCM Projects

LCM Projects

Other (as of 8 February 2024)

Phase I

Phase I

Phase II

Phase II

Phase III

Phase III

LCM Projects

LCM Projects

Removed since last quarter

Veeva ID: Z4-57208
Date of preparation: August 2023